XEOMIN

This brand name is authorized in United States. It is also authorized in Australia, Austria, Brazil, Canada, Croatia, Cyprus, Ecuador, Estonia, Finland, France, Hong Kong SAR China, Ireland, Israel, Japan, Lithuania, Malta, Netherlands, New Zealand, Poland, Romania, Singapore, South Africa, Spain, UK.

Active ingredients

The drug XEOMIN contains one active pharmaceutical ingredient (API):

1	Botulinum toxin type A UNII E211KPY694 - BOTULINUM TOXIN TYPE A
	Botulinum toxin type A is a protein complex derived from Clostridium botulinum. The protein consists of type A neurotoxin and several other proteins. Under physiological conditions it is presumed that the complex dissociates and releases the pure neurotoxin. Intramuscular injection of the neurotoxin complex blocks cholinergic transport at the neuromuscular junction by preventing the release of acetylcholine. The nerve endings of the neuromuscular junction no longer respond to nerve impulses and secretion of the chemotransmitter is prevented (chemical denervation).
	Read more about Botulinum toxin type A

Medication package inserts

Below package inserts are available for further reading:

Document	Type	Information Source
XEOMIN Powder for solution for injection	MPI, US: SPL/PLR	FDA, National Drug Code (US)

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC Group		Classification
M03AX01	Botulinum toxin	M Musculo-skeletal system → M03 Muscle relaxants → M03A Muscle relaxants, peripherally acting agents → M03AX Other muscle relaxants, peripherally acting agents
Discover more medicines within M03AX01

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
AU	Pharmaceutical Benefits Scheme	10994P, 11005F, 12087E
BR	Câmara de Regulação do Mercado de Medicamentos	587620050000117
CA	Health Products and Food Branch	02324032, 02371081, 02383489
EC	Agencia Nacional de Regulación, Control y Vigilancia Sanitaria	104-MBE-0617, 122-MBE-0218
EE	Ravimiamet	1620267, 1620278, 1620289, 1620290, 1620302, 1620313, 1620324, 1620335, 1620346, 1654589, 1654590, 1654602, 1654613, 1654624
ES	Centro de información online de medicamentos de la AEMPS	69292, 74067, 80801
FI	Lääkealan turvallisuus- ja kehittämiskeskus	093306, 120109, 552192
FR	Base de données publique des médicaments	67411667, 67540690, 69086891
GB	Medicines & Healthcare Products Regulatory Agency	134524, 194314, 333432
HK	Department of Health Drug Office	63224, 63225
HR	Agencija za lijekove i medicinske proizvode	HR-H-480570177, HR-H-601583942, HR-H-708914098
IL	מִשְׂרַד הַבְּרִיאוּת	8427, 8428
JP	医薬品医療機器総合機構	1229407E1029, 1229407E2025, 1229407E3021
LT	Valstybinė vaistų kontrolės tarnyba	1070625, 1070626, 1072736, 1072737, 1072738, 1072739, 1072740, 1072741, 1072742, 1073737, 1080251, 1080252, 1080253, 1080254
MT	Medicines Authority	MA025/00701, MA025/00702, MA025/00703
NL	Z-Index G-Standaard, PRK	115967, 115975, 134759
NZ	Medicines and Medical Devices Safety Authority	16626, 16643
PL	Rejestru Produktów Leczniczych	100192798, 100252030, 100368814
RO	Agenția Națională a Medicamentului și a Dispozitivelor Medicale	W60612001, W60612002, W60612003, W60612004, W60612005, W60612006, W60612007, W60612008, W60612009, W60613001, W60613002, W60613003, W60613004, W60613005, W60613006, W60613007, W62943001, W62943002, W62943003, W62943004, W62943005, W62943006, W62943007, W62943008, W62943009
SG	Health Sciences Authority	14585P, 14586P
US	FDA, National Drug Code	0259-1605, 0259-1610, 0259-1620, 0259-4110, 0259-4150, 46783-160, 46783-161, 46783-165
ZA	Health Products Regulatory Authority	53/30.5/0223, 53/30.5/0224